Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 21Colorectal Neoplasms 5HER2-positive Breast Cancer 4Brain Neoplasms 4Neoplasms 3Meningeal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage IA Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × tucatinib × 1 year × Clear all
NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡